Phase II Trial of capsaicin gel application for prevent oxaliplatin-induced peripheral neuropathy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20150720002

Enrollment

Registered

2015-07-20

Start date

2015-07-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxaliplatin Colorectal cancer Gastric cancer Biliary tract cancer Pancreatic cancer Colorectal neoplasms Stomach neoplasms Biliary tract neoplasms Pancreatic neoplasms Oxaliplatin Peripheral Nervous System Diseases

Interventions

0.025% w/w Capsaicin gel

Experimental Drug

Capsaicin gel

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent Pathologic confirmed of colorectal cancer, gastric cancer, biliary tract cancer or pancreatic cancer Planned to receive at least 800mg per meter square of oxaliplatin ECOG PS 0 - 2 Never received paclitaxel, docetaxel, cisplatin, carboplatin and oxaliplatin

Exclusion criteria

Exclusion criteria: Impaired liver or kidney function Presence of any grade peripheral neuropathy from any cause Presence of wound at hand or foot Presence of any condition that limit application of study drug Currently use gabapentin, Amitriptyline or Nortriptyline

Design outcomes

Primary

Measure	Time frame
Grade D or more peripheral neuropathy - free rate (From Grade A to E) 4 weeks after last dose of chemotherapy Patient Neurotoxicity Questionnaire (Thai version)	—

Secondary

Measure	Time frame
Grade 2 or more peripheral neuropathy - free rate (From Grade 0 - 5) 4 weeks after last dose of chemotherapy Common Terminology Criteria of Adverse Events version 4.03,Time to develop any grade peripheral neuropathy Time from first date of chemotherapy to first date of any grade of peripheral neurpathy Patient Neurotoxicity Questionnaire (Thai version),Oxaliplatin dose to develop any grade peripheral neuropathy Cumulative dose of oxaliplatin that develop any grade of peripheral neurpathy Patient Neurotoxicity Questionnaire (Thai version),Adverse event From first date of chemotherapy to 4 weeks after last dose of chemotherapy Common Terminology Criteria of Adverse Events version 4.03	—

Measure

Time frame

Grade 2 or more peripheral neuropathy - free rate (From Grade 0 - 5) 4 weeks after last dose of chemotherapy Common Terminology Criteria of Adverse Events version 4.03,Time to develop any grade peripheral neuropathy Time from first date of chemotherapy to first date of any grade of peripheral neurpathy Patient Neurotoxicity Questionnaire (Thai version),Oxaliplatin dose to develop any grade peripheral neuropathy Cumulative dose of oxaliplatin that develop any grade of peripheral neurpathy Patient Neurotoxicity Questionnaire (Thai version),Adverse event From first date of chemotherapy to 4 weeks after last dose of chemotherapy Common Terminology Criteria of Adverse Events version 4.03

—

Countries

Thailand

Contacts

Public ContactChutima Upachar

Bhumibol Adulyadej Hospital

chutima2576@yahoo.com025347322

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Phase II Trial of capsaicin gel application for prevent oxaliplatin&#45;induced peripheral neuropathy